Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 7/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 7/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 7/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 3/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | BRAF | P15056 | 2/20 | 0.56 |
| ▸ | GCGR | P47871 | 6/20 | 0.56 |
| ▸ | GSK3B | P49841 | 3/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.55 |
| ▸ | FRK | P42685 | 2/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.55 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.55 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.55 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6423292 | 1.00 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL10992179 | 0.91 | MAPK14 (0.83) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL8861944 | 0.90 | MAPK14 (0.81) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| Hydrochloric Acid SCHEMBL30023185 | 0.89 | MAPK14 (0.80) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL1387736 | 0.82 | KDM4E (0.81) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL4882839 | 0.82 | KDM4E (0.81) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL6601244 | 0.81 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL11272961 | 0.81 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7087770 | 0.80 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL4536537 | 0.80 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247558-B2 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-2247558-B1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2022-02-02 | — | — | EP | disclosed |
| US-20090098536-A1 | Method for subgroup analysis in subjects having or being suspected of having inflammatory disease, use of anti-p38MAPK antibodies, kits and their use | C-A-I-R- BIOSCIENCES GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| CN-100443481-C | Imidazolyl-cyclic acetals | RHONE POULENC RORER LTD (GB) | 2008-12-17 | — | — | CN | disclosed |
| EP-1909102-A1 | Method for subgroup analysis in subjects having or being suspected of having inflammatory disease, use of anti-p38mapk antibodies, kits and their use | c-a-i-r biosciences GmbH (DE) | 2008-04-09 | — | — | EP | disclosed |
| EP-0988301-B1 | IMIDAZOLYL-CYCLIC ACETALS | AVENTIS PHARMA LTD (GB) | 2006-08-09 | — | — | EP | disclosed |
| US-6989395-B2 | Imidazolyl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2006-01-24 | — | — | US | disclosed |
| US-20040038991-A1 | Imidazolyl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2004-02-26 | — | — | US | disclosed |
| US-6602877-B1 | Imidazolyl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2003-08-05 | — | — | US | disclosed |
| CN-1273584-A | Imidazolyl-cyclic acetals | RHONE POULENC RORER LTD (GB) | 2000-11-15 | — | — | CN | disclosed |
| EP-0988301-A1 | IMIDAZOLYL-CYCLIC ACETALS | RHONE-POULENC RORER LIMITED (GB) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998056788-A1 | IMIDAZOLYL-CYCLIC ACETALS | RHONE-POULENC RORER LIMITED (GB) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038991-A1 | Imidazolyl-cyclic acetals | CBR1, LBR, CBR3 | MAPK14 1915/4885MAPK13 1610/4885MAPK12 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.